Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302312 · ClinicalTrials.gov registry record
Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Acceptability
A clinical trial, sponsored by RTI International.
- Completed
- Registry status
- 54
- Enrollment target
NCT03302312: Completed study, sponsored by RTI International.
NCT03302312 is a clinical trial that has completed, run by RTI International. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03302312 has completed, sponsored by RTI International.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
This qualitative study will use focus groups, small group interviews, and individual interviews (both in person and over the phone) to compile a range of perspectives on service members' decision-making processes and information needs related to Stellate Ganglion Block (SGB). Participants will include service members, spouses, and providers.
Primary Outcome
Discussion topic areas: * Context for mental health and treatment * Advantages and drawbacks of treatment options * Information and decision-making * Experience and expectations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-11-03 |
| Est. Completion | 2018-03-02 |
What the finished NCT03302312 record still lists
NCT03302312 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03302312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03302312 about?
NCT03302312 is a clinical study titled "Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Acceptability". This qualitative study will use focus groups, small group interviews, and individual interviews (both in person and over the phone) to compile a range of perspectives on service members' decision-making processes and information needs related to Stellate Ganglion Block (SGB). Participants will inclu...
What is the current status of trial NCT03302312?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2017-11-03. Estimated completion is 2018-03-02.
Who is sponsoring clinical trial NCT03302312?
This trial is sponsored by RTI International, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI